New York 2025 Session Status: Introduced

A11524 — Requires the fee schedule for appropriate current procedural terminology and proprietary laboratory analysis codes be regularly updated for all mandatory biomarker precision medical testing coverage

Last action — In Assembly Committee

  1. 1
    Introduced
  2. 2
    In Committee
  3. 3
    Passed Assembly
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill has been introduced in the Assembly. Introduced May 28, 2026. It must pass committee before a floor vote.

Next likely step: a committee referral and hearing.

Odds of enactment

Low chance

Based on the sponsor, cosponsors, and committee posture, this bill has a low chance of becoming law.

Upgrade to see the exact probability and what's driving it.

A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.

Prognosis

Not enough signal yet

Not enough signal yet to read this bill's trajectory — we surface a likelihood only once there's real movement (stage, sponsorship, committee, or votes) to point to.

Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.

In plain language

The bill mandates regular updates to fee schedules for biomarker precision medical testing coverage.

This bill requires the Department of Health to create and continually update a fee schedule for biomarker precision medical testing. This ensures that medical facilities are compensated fairly for these essential tests.

What this means for you
  • Healthcare: This means healthcare providers will have a clear and updated compensation structure for conducting precision medical tests.

Summary

Requires the fee schedule for appropriate current procedural terminology and proprietary laboratory analysis codes be established and regularly updated for all mandatory biomarker precision medical testing coverage by the department of health.

Bill Text

Action History

  1. REFERRED TO HEALTH

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 218 not signed on

Sponsors (1)

Co-sponsors (0)

None.

Not signed on (218)

218 members have not signed on to this bill.

Show all 218 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does A11524 do?
Requires the fee schedule for appropriate current procedural terminology and proprietary laboratory analysis codes be established and regularly updated for all mandatory biomarker precision medical testing coverage by the department of health.
Who sponsors A11524?
A11524 is sponsored by Pamela J. Hunter.
What is the current status of A11524?
This bill has been introduced in the Assembly. Introduced May 28, 2026. It must pass committee before a floor vote.
Where can I track A11524?
Track A11524 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on A11524

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of A11524

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →